Wall Street analysts forecast that Aimmune Therapeutics Inc (NASDAQ:AIMT) will announce ($0.74) earnings per share for the current fiscal quarter, Zacks reports. Zero analysts have made estimates for Aimmune Therapeutics’ earnings, with estimates ranging from ($0.93) to ($0.57). Aimmune Therapeutics reported earnings per share of ($0.65) during the same quarter last year, which indicates a negative year-over-year growth rate of 13.8%. The business is scheduled to issue its next earnings report on Tuesday, August 14th.
According to Zacks, analysts expect that Aimmune Therapeutics will report full year earnings of ($3.14) per share for the current financial year, with EPS estimates ranging from ($3.74) to ($2.27). For the next fiscal year, analysts anticipate that the business will post earnings of ($2.92) per share, with EPS estimates ranging from ($3.75) to ($2.21). Zacks Investment Research’s earnings per share averages are an average based on a survey of sell-side research analysts that that provide coverage for Aimmune Therapeutics.
Aimmune Therapeutics (NASDAQ:AIMT) last announced its quarterly earnings data on Tuesday, May 8th. The biotechnology company reported ($0.92) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.71) by ($0.21). During the same period in the previous year, the firm posted ($0.52) earnings per share.
AIMT has been the topic of a number of analyst reports. Zacks Investment Research upgraded Aimmune Therapeutics from a “hold” rating to a “buy” rating and set a $34.00 price objective on the stock in a research report on Friday, May 4th. Cantor Fitzgerald reiterated an “overweight” rating and set a $64.00 price objective on shares of Aimmune Therapeutics in a research report on Monday, March 5th. Credit Suisse Group set a $47.00 price objective on Aimmune Therapeutics and gave the stock a “buy” rating in a research report on Monday, March 5th. Royal Bank of Canada lifted their price objective on Aimmune Therapeutics to $62.00 and gave the stock an “outperform” rating in a research report on Tuesday, February 27th. Finally, Piper Jaffray Companies set a $62.00 price objective on Aimmune Therapeutics and gave the stock a “buy” rating in a research report on Tuesday, February 27th. One analyst has rated the stock with a hold rating, nine have assigned a buy rating and one has given a strong buy rating to the company. The stock currently has a consensus rating of “Buy” and a consensus target price of $53.67.
Shares of Aimmune Therapeutics stock opened at $30.20 on Monday. Aimmune Therapeutics has a one year low of $18.25 and a one year high of $42.00. The company has a market cap of $1.78 billion, a P/E ratio of -11.57 and a beta of -0.34.
In other Aimmune Therapeutics news, insider Douglas T. Sheehy sold 3,296 shares of the firm’s stock in a transaction on Tuesday, May 22nd. The stock was sold at an average price of $33.00, for a total transaction of $108,768.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CFO Eric Bjerkholt bought 1,600 shares of the business’s stock in a transaction on Wednesday, June 13th. The shares were acquired at an average cost of $30.41 per share, with a total value of $48,656.00. The disclosure for this purchase can be found here. In the last three months, insiders have sold 364,493 shares of company stock valued at $11,580,119. 24.56% of the stock is owned by insiders.
A number of hedge funds have recently bought and sold shares of AIMT. Carillon Tower Advisers Inc. acquired a new stake in Aimmune Therapeutics during the fourth quarter worth $58,838,000. Alliancebernstein L.P. increased its stake in Aimmune Therapeutics by 109.5% during the fourth quarter. Alliancebernstein L.P. now owns 1,400,281 shares of the biotechnology company’s stock worth $52,959,000 after acquiring an additional 731,927 shares during the last quarter. Victory Capital Management Inc. increased its stake in Aimmune Therapeutics by 936.4% during the first quarter. Victory Capital Management Inc. now owns 664,641 shares of the biotechnology company’s stock worth $21,155,000 after acquiring an additional 600,510 shares during the last quarter. Franklin Resources Inc. acquired a new stake in Aimmune Therapeutics during the fourth quarter worth $18,702,000. Finally, Loomis Sayles & Co. L P acquired a new stake in Aimmune Therapeutics during the first quarter worth $14,429,000. 79.49% of the stock is owned by institutional investors.
Aimmune Therapeutics Company Profile
Aimmune Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes product candidates for the treatment of peanut and other food allergies. Its lead Characterized Oral Desensitization ImmunoTherapy product candidate is AR101, an investigational biologic for the treatment of patients with peanut allergy.
Get a free copy of the Zacks research report on Aimmune Therapeutics (AIMT)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Aimmune Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aimmune Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.